HK1041817A1 - Drug combinations comprising (e)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4. - Google Patents

Drug combinations comprising (e)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4.

Info

Publication number
HK1041817A1
HK1041817A1 HK02103512A HK02103512A HK1041817A1 HK 1041817 A1 HK1041817 A1 HK 1041817A1 HK 02103512 A HK02103512 A HK 02103512A HK 02103512 A HK02103512 A HK 02103512A HK 1041817 A1 HK1041817 A1 HK 1041817A1
Authority
HK
Hong Kong
Prior art keywords
ämethyl
ylü
aminoüpyrimidin
dihydroxyhept
isoenzyme
Prior art date
Application number
HK02103512A
Other languages
English (en)
Inventor
Ali Raza
John Stuart Pears
Howard Gerard Hutchinson
Dennis Schneck
Takahiko Baba
Akira Touchi
Yoshitaka Yamaguchi
Original Assignee
Astrazeneca Ab
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1041817(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Application filed by Astrazeneca Ab, Shionogi & Co filed Critical Astrazeneca Ab
Publication of HK1041817A1 publication Critical patent/HK1041817A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK02103512A 1999-02-06 2002-05-08 Drug combinations comprising (e)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4. HK1041817A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
PCT/GB2000/000278 WO2000045817A1 (en) 1999-02-06 2000-02-01 Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4

Publications (1)

Publication Number Publication Date
HK1041817A1 true HK1041817A1 (en) 2002-07-26

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103512A HK1041817A1 (en) 1999-02-06 2002-05-08 Drug combinations comprising (e)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4.

Country Status (29)

Country Link
US (3) US6982157B1 (xx)
EP (1) EP1185274B1 (xx)
JP (2) JP2002536331A (xx)
KR (2) KR20010101790A (xx)
CN (1) CN1165310C (xx)
AR (1) AR029333A1 (xx)
AT (1) ATE282415T1 (xx)
AU (1) AU767304B2 (xx)
BR (1) BR0007999A (xx)
CA (1) CA2358632C (xx)
CZ (1) CZ301296B6 (xx)
DE (1) DE60015965T2 (xx)
EE (1) EE04929B1 (xx)
EG (1) EG23858A (xx)
ES (1) ES2232418T3 (xx)
GB (1) GB0000710D0 (xx)
HK (1) HK1041817A1 (xx)
ID (1) ID30485A (xx)
IL (1) IL144715A0 (xx)
IS (1) IS2337B (xx)
MX (1) MXPA01007905A (xx)
MY (1) MY130606A (xx)
NO (1) NO320745B1 (xx)
NZ (1) NZ512982A (xx)
PL (1) PL198034B1 (xx)
PT (1) PT1185274E (xx)
TR (1) TR200102228T2 (xx)
TW (1) TWI282738B (xx)
WO (1) WO2000045817A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US7658944B2 (en) 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1786414A4 (en) 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
WO2007005941A2 (en) 2005-07-05 2007-01-11 President And Fellows Of Harvard College Liver targeted conjugates
CN101330919B (zh) * 2005-12-20 2012-12-05 力奇制药公司 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
CA3103616A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
JP2022542004A (ja) 2019-07-31 2022-09-29 インタス ファーマシューティカルズ リミテッド ＨＭＧ－ＣｏＡレダクターゼ阻害剤及びフェノフィブラートを含む医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DK0521417T3 (da) * 1991-07-02 1995-03-27 Benckiser Gmbh Joh A Sammenklappelig forrådsflaske
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
AU1289899A (en) * 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity

Also Published As

Publication number Publication date
IS6009A (is) 2001-07-17
IL144715A0 (en) 2002-06-30
EG23858A (en) 2007-11-18
GB0000710D0 (en) 2000-03-08
ID30485A (id) 2001-12-13
CN1338936A (zh) 2002-03-06
MXPA01007905A (es) 2003-06-04
US20060040969A1 (en) 2006-02-23
TWI282738B (en) 2007-06-21
AU767304B2 (en) 2003-11-06
NZ512982A (en) 2003-08-29
EP1185274B1 (en) 2004-11-17
PL364780A1 (en) 2004-12-13
PT1185274E (pt) 2005-03-31
NO20013811L (no) 2001-10-02
NO320745B1 (no) 2006-01-23
DE60015965T2 (de) 2006-01-05
EE200100406A (et) 2002-10-15
WO2000045817A1 (en) 2000-08-10
US20090042911A1 (en) 2009-02-12
DE60015965D1 (de) 2004-12-23
CN1165310C (zh) 2004-09-08
CA2358632A1 (en) 2000-08-10
TR200102228T2 (tr) 2002-03-21
CZ20012844A3 (cs) 2001-11-14
ATE282415T1 (de) 2004-12-15
JP2002536331A (ja) 2002-10-29
PL198034B1 (pl) 2008-05-30
ES2232418T3 (es) 2005-06-01
CZ301296B6 (cs) 2010-01-06
CA2358632C (en) 2008-10-28
NO20013811D0 (no) 2001-08-03
EE04929B1 (et) 2007-12-17
AR029333A1 (es) 2003-06-25
EP1185274A1 (en) 2002-03-13
IS2337B (is) 2008-02-15
KR20010101790A (ko) 2001-11-14
JP2007277267A (ja) 2007-10-25
US6982157B1 (en) 2006-01-03
AU2121800A (en) 2000-08-25
BR0007999A (pt) 2001-11-06
MY130606A (en) 2007-07-31
KR20060117381A (ko) 2006-11-16

Similar Documents

Publication Publication Date Title
HK1041817A1 (en) Drug combinations comprising (e)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4.
DE60045168D1 (de) Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure
TR200103216T2 (tr) Pirimidinon bileşimleri
BR9908280A (pt) Inibidores de enzimas de fosfolipase
AP2004003189A0 (en) Use of CETP inhibitors and optionally HMG COA reductase inhibitors and/or antihypertensive agents.
MXPA03007049A (es) Inhibidores heterociclicos de erk2 y usos de los mismos.
HK1041693A1 (en) Dimeric compounds and as inhibitors of neuraminidase.
WO2004112482A8 (en) Biological active coating components, coatings, and coated surfaces
AU6111000A (en) Inhibitors of viral helcase
AU2003224371A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
AU2003239544A1 (en) Amplification and overexpression of oncogenes
ATE264328T1 (de) Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
WO2004027056A3 (en) Methods of use for thermostable rna ligases
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
EP1553170A4 (en) NEW CARBONYL REDUCTASE, THEIR GENE AND METHOD OF USE THEREOF
AU2002341799A1 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
WO2003017925A3 (en) Treatment of type i diabetes
AU2003254064A1 (en) Amplification and overexpression of oncogenes
SI1185274T1 (en) Drug combinations comprising (e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
HUP0104977A3 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
AU5530800A (en) Method and composition for enhancing the activity of an enzyme
AU2002336967A1 (en) 2, 5-substituted 1-(aminocarbonylalkyl) -pyrimidin-4-one derivatives with lp-pla2 inhinitory activity for the treatment of atherosclerosis
AU1270801A (en) Phosphostannate or borostannate pyrolitic coating, and glazing comprising same
AU2002318429A1 (en) Usp-3like deubiquitinating enzyme gene disruptions, compositions and methods related thereto